8 Best Life Sciences Penny Stocks to Buy
In this article, we will look at some of the best penny stocks in the life sciences sector that currently offer attractive upside potential for investors.
Nautilus Biotechnology Inc. (NAUT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 11,634,211 | $21,755,974 | -8% | 0.33% |
| 2. | A16z Capital Management Marc Andreessen And Ben Horowitz | 9,063,054 | $16,947,911 | -49% | 0.12% |
| 3. | Cercano Management Chris Orndorff | 7,172,985 | $13,413,482 | 1.79% | |
| 4. | Citadel Investment Group Ken Griffin | 1,896,192 | $3,545,879 | 0% | |
| 5. | Renaissance Technologies Jim Simons | 690,514 | $1,291,261 | +160% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.61 | 25,000 | $65,237.50 | 10,366,721 | 2026-03-04 | Filing | |
| $1.49 | 4,000 | $5,960.00 | 4,000 | 2025-11-06 | Filing | |
| $0.68 | 83,500 | $57,030.50 | 10,341,721 | 2025-09-08 | Filing | |
| $0.67 | 116,500 | $78,544.30 | 10,258,221 | 2025-09-05 | Filing | |
| $0.64 | 20,000 | $12,858.00 | 74,140 | 2025-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.35 | 384,026 | $902,461.10 | 971,885 | 2026-06-02 | Filing | |
| $2.35 | 4,615,974 | $10,847,538.90 | 11,682,032 | 2026-06-02 | Filing | |
| $2.87 | 47,031 | $134,743.82 | 0 | 2024-09-23 | Filing | |
| $2.85 | 35,000 | $99,869.00 | 0 | 2024-09-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 26,000 | $40,560 | 0% | |
| 2. | 10,000 | $18,200 | 0% | |
| 3. | 12,000 | $17,040 | 0.01% | |
| 4. | 3,547 | $5,037 | 0% | |
| 5. | 14,000 | $19 | 0% |
News See All
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript February 26, 2026Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.14.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript October 28, 2025 Operator: Good day and thank you for standing by.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2025 Earnings Call Transcript August 1, 2025 Operator: Good day, ladies and gentlemen, and thank you for standing by.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript April 29, 2025Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.14.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good day, and thank you for standing by.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript October 29, 2024Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.17.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Call Transcript July 30, 2024Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.14, expectations were $-0.16.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript April 30, 2024 Nautilus Biotechnology, Inc. beats earnings expectations.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript February 28, 2024 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $-0.16.